- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07796776
The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each Condition (TDP-signatures)
26. august 2026 opdateret af: Stefano Previtali, IRCCS San Raffaele
Comparative Analysis of TDP-43 Pathology in Skeletal Muscle Biopsies With Electrostimulation for Enhanced Neuromuscular Junction Sampling in Patients Affected by Inclusion Body Myopathy (IBM) and Motor Neuron Disease (MND)
The aim of the study is to characterize 30 patients exhibiting muscular atrophy and weakness who require a muscle biopsy for diagnosis (suspected inclusion body myopathy vs atypical motor neuron disease), through an innovative technique (a muscle biopsy with Electrostimulation for Enhanced Neuromuscular Junction sampling), to evaluate the involvement of the neuromuscular junction in each disease and to better characterize shared and divergent patterns of TDP-43 pathology within the peripheral nervous system in both disorders.
Studieoversigt
Status
Aktiv, ikke rekrutterende
Undersøgelsestype
Observationel
Tilmelding (Anslået)
30
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Milan, Italien
- IRCCS Ospedale San Raffaele
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
N/A
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
30 adult patients with a neuromuscular disorder (suspected IBM or in differential diagnosis between IBM and MND)
Beskrivelse
Inclusion Criteria:
- Patients exhibiting progressive muscle weakness and atrophy with a classic clinical IBM pattern or with an atypical clinical IBM pattern or with an atypical MND pattern
- Able to understand and sign the informed consent
- Treated according to standard of care clinical practice
Exclusion Criteria:
- Contraindications to needle EMG or skeletal muscle biopsy
- Psychiatric diseases that may interfere with adherence to the follow-up protocol
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Motor neuron sygdom
|
|
Inclusion body myopathy
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic sensitivity of an integrated clinical, neurophysiological, metabolic and histopathological model in the differential diagnosis between IBM and MND.
Tidsramme: At the end of the follow-up period (24 months of follow-up)
|
To achieve a diagnostic sensitivity of >90% for the differential diagnosis between IBM and MND integrating clinical variables (site of onset, scales reflecting disease progression rate, muscle strength), neurophysiological indices (presence and degree of active denervation signs, presence of myopathic or neurogenic motor unit potentials), histopathological parameters (myopathic or neuropathic pattern of disease) and metabolic measures (hyper- vs hypo-metabolism) into a multivariable binary logistic regression model, using the final diagnosis confirmed during longitudinal follow-up as the reference standard.
|
At the end of the follow-up period (24 months of follow-up)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
To evaluate signs of muscle and neuromuscular junction (NMJ) involvement at neuropathological level in each disease
Tidsramme: At the end of the follow-up period (24 months of follow-up)
|
To investigate disease-specific histological signatures, comparing the pattern of fiber degeneration, the presence of inflammatory infiltrates, the presence of protein aggregation markers (such as pTDP-43) and their localization, the presence of mitochondrial changes (the percentage of age-exceeding number of COX-negative fibers) and the NMJ involvement by evaluating the presynaptic and postsynaptic integrity (quantified as the percentage of synaptophysin and Ach-R clustering, respectively) between IBM and MND (through Fisher's exact test or Mann-Whitney U test, as appropriate) and to evaluate the prognostic role of each histological parameter (through Kaplan-Meier followed by log-rank test and Cox proportional hazards regression).
|
At the end of the follow-up period (24 months of follow-up)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. juli 2026
Primær færdiggørelse (Anslået)
1. juli 2028
Studieafslutning (Anslået)
1. juli 2030
Datoer for studieregistrering
Først indsendt
20. august 2026
Først indsendt, der opfyldte QC-kriterier
26. august 2026
Først opslået (Faktiske)
1. september 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
1. september 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
26. august 2026
Sidst verificeret
1. august 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Muskuloskeletale sygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Muskelsygdomme
- Neuromuskulære sygdomme
- Metaboliske sygdomme
- Neurodegenerative sygdomme
- Rygmarvssygdomme
- TDP-43 Proteinopatier
- Proteostase mangler
- Motor neuron sygdom
- Myositis
- Ernæringsmæssige og metaboliske sygdomme
- Amyotrofisk lateral sklerose
- Myositis, Inklusionslegeme
Andre undersøgelses-id-numre
- TDP-signatures
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .